allogeneic gamma-delta t cells
Cell therapyexperimental
Clinical trial activity
15 trials · 14 clinical orgs · 0 marketing orgs
Phase 1
13
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2018 (NCT03575299)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
- Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis · Phase 1
- Arthritis, Rheumatoid · Phase 1
- Autoimmune Diseases · Phase 1
- Burkitt Lymphoma · Phase 1
- Carcinoma, Hepatocellular · Phase 1
- Hematologic Diseases · Phase 1
- Leukemia, Myeloid, Acute · Phase 1
- Lupus Erythematosus, Systemic · Phase 1
- Lupus Nephritis · Phase 1
- Lymphoma · Phase 1
- Lymphoma, B-Cell · Phase 1
- Lymphoma, B-Cell, Marginal Zone · Phase 1
- Lymphoma, Follicular · Phase 1
- Lymphoma, Large B-Cell, Diffuse · Phase 1
- Lymphoma, Mantle-Cell · Phase 1
- Lymphoma, Non-Hodgkin · Phase 1
- Lymphoma, T-Cell · Early Phase 1
- Melanoma · Early Phase 1
- Myositis · Phase 1
- Neoplasms · Phase 1/Phase 2
- Sclerosis · Phase 1
- Stiff-Person Syndrome · Phase 1
- Tuberculosis, Multidrug-Resistant · Phase 1
Mechanism of action
- T-lymphocytesSupplementation
T-lymphocytes supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07100873 | Phase 1 | Aug 15, 2025 | Adicet Therapeutics |
| NCT07126782 | Early Phase 1 (Phase 1) | Jul 20, 2025 | China Academy of Chinese Medical Sciences |
| NCT07237230 | N/A | Jul 1, 2025 | Huazhong University of Science and Technology |
| NCT07144735 | N/A | Apr 1, 2025 | Changping Laboratory, Peking University |
| NCT06375993 | Phase 1 | Nov 30, 2024 | Adicet Therapeutics |
| NCT06364787 | Phase 1 | Apr 26, 2024 | Beijing GD Initiative Cell Therapy Technology Co.，Ltd., Chinese Academy of Medical Sciences, People's Liberation Army of China |
| NCT06364800 | Early Phase 1 (Phase 1) | Apr 26, 2024 | Beijing GD Initiative Cell Therapy Technology Co.，Ltd., Chinese Academy of Medical Sciences, People's Liberation Army of China |
| NCT06212388 | Early Phase 1 (Phase 1) | Jan 24, 2024 | Beijing GD Initiative Cell Therapy Technology Co.，Ltd., Xijing Hospital |
| NCT05755854 | Phase 1 | May 3, 2023 | Anhui Medical University |
| NCT04735471 | Phase 1 | Mar 4, 2021 | Adicet Bio |
| NCT04765462 | Phase 1/Phase 2 (Phase 2) | Mar 1, 2021 | People's Liberation Army of China |
| NCT04696705 | Early Phase 1 (Phase 1) | Dec 31, 2020 | Beijing GD Initiative Cell Therapy Technology Co.，Ltd., Chinese Academy of Medical Sciences |
| NCT04518774 | Early Phase 1 (Phase 1) | Aug 15, 2020 | Beijing GD Initiative Cell Therapy Technology Co.，Ltd., Chinese Academy of Medical Sciences, People's Liberation Army of China |
| NCT03790072 | Phase 1 | Nov 27, 2018 | TC Biopharm |
| NCT03575299 | Phase 1 | Jun 1, 2018 | Jinan University, Shenzhen Third People's Hospital |
Showing 15 of 15 trials
Page 1 / 1
Organizations
Research & Development (14)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Beijing GD Initiative Cell Therapy Technology Co.，Ltd. | Government | 5 | 0 | 1 | 2020 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 4 | 1 | 1 | 2020 |
| People's Liberation Army of China | Government | 4 | 4 | 2 | 2020 |
| Adicet Therapeutics | For profit | 2 | 2 | 1 | 2024 |
| Adicet Bio | For profit | 1 | 1 | 1 | 2021 |
| Anhui Medical University | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Changping Laboratory | Academic/Hospital | 1 | 0 | 1 | 2025 |
| China Academy of Chinese Medical Sciences | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Huazhong University of Science and Technology | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Jinan University | Academic/Hospital | 1 | 1 | 1 | 2018 |
| Peking University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Shenzhen Third People's Hospital | Academic/Hospital | 1 | 0 | 1 | 2018 |
| TC Biopharm | For profit | 1 | 1 | 1 | 2018 |
| Xijing Hospital | Academic/Hospital | 1 | 1 | 1 | 2024 |
14 organizations
Page 1 / 1